← Research index  ·  Disorder page  ·  Source YAML

Cross-provider research synthesis

Arterial Tortuosity Syndrome

MONDO:0008818 Curated 2026-07-04T00:00:00Z 9 harmonized findings
falcon · 32 citations openscientist · 39 citations
Concordant asserts the finding Partial supports a weaker/qualified form Contradictory conflicts with it Silent does not address it

Harmonized findings

Arterial tortuosity syndrome is an autosomal recessive connective tissue disorder caused by biallelic (homozygous or compound heterozygous) loss-of-function variants in SLC2A10, encoding the facilitative glucose transporter GLUT10.

UNANIMOUS INTEGRATED
genetic_factorpathophysiology
ProviderStanceScoreEvidence
falcon CONCORDANT 95% carrying two pathogenic alleles in SLC2A10 is causal
Falcon states biallelic SLC2A10 (GLUT10) pathogenic variants are the primary cause and inheritance is autosomal recessive.
DOI:10.1038/gim.2017.253
openscientist CONCORDANT 95% Mutations in one of these genes, SLC2A10, encoding the facilitative glucose transporter GLUT10, were identified in six ATS families.
OpenScientist quotes the original discovery paper identifying SLC2A10/GLUT10 and frames ATS as a monogenic autosomal recessive disorder from biallelic loss-of-function variants.
PMID:16550171

GLUT10 functions as a dehydroascorbic acid transporter across endomembranes, so its deficiency impairs intracellular ascorbate compartmentalization, framing ATS as an ascorbate compartmentalization disorder.

MAJORITY INTEGRATED
gene_functionpathophysiology
ProviderStanceScoreEvidence
openscientist CONCORDANT 95% The present results demonstrate that GLUT10 is a DAA transporter and DAA transport is diminished in the endomembranes of fibroblasts from ATS patients
OpenScientist cites experimental confirmation that GLUT10 is a DAA transporter and explicitly characterizes ATS as an ascorbate compartmentalization disorder.
PMID:27153185, PMID:32307537
falcon PARTIAL 60% GLUT10 is described as an intracellular transporter involved in dehydroascorbic acid/ascorbate biology and connective-tissue homeostasis
Falcon presents the GLUT10 dehydroascorbic-acid/ascorbate role as a mechanistic hypothesis rather than confirmed transporter function, and does not use the "ascorbate compartmentalization disorder" framing.
DOI:10.1038/gim.2017.253

The downstream vascular pathology features fragmented elastic fibers with a fragmented elastin core and disorganized/increased collagen in the arterial wall, reflecting defective extracellular matrix assembly.

UNANIMOUS INTEGRATED
pathophysiology
ProviderStanceScoreEvidence
falcon CONCORDANT 90% EM demonstrates a fragmented elastin core with peripheral microfibrils of random directionality
Falcon reports fragmented elastic fibers and increased collagen deposition on human skin/vascular biopsy, with a fragmented elastin core on EM.
DOI:10.1038/gim.2017.253
openscientist CONCORDANT 90% EM of skin EF shows a fragmented elastin core and a peripheral mantle of microfibrils of random directionality
OpenScientist reports the same ultrastructural elastin/collagen findings and adds disorganized medial smooth muscle cells with a discontinuous internal elastic lamina.
PMID:29323665, PMID:35302653

The hallmark clinical phenotype is generalized tortuosity, elongation, and stenosis of large- and medium-sized arteries, with variable aneurysm formation.

UNANIMOUS INTEGRATED
phenotype
ProviderStanceScoreEvidence
falcon CONCORDANT 90% abnormal twisting/turning and elongation of arteries leading to altered hemodynamics and potential downstream stenosis/ischemia
Falcon defines the core vascular concept as arterial elongation/tortuosity with downstream stenosis, and tabulates high frequencies of aortic and multisite arterial tortuosity.
DOI:10.1038/gim.2017.253
openscientist CONCORDANT 90% Stenoses, tortuosity, and aneurysm formation are widespread occurrences.
OpenScientist reports widespread stenoses, tortuosity, and aneurysm formation as the hallmark cardiovascular phenotype.
PMID:29323665

The role of TGF-beta signaling is unresolved: canonical upregulation was reported in the original discovery, but end-stage patient tissue does not show increased canonical (pSMAD2/CTGF) signaling, so canonical TGF-beta may not be the primary disease driver.

UNANIMOUS INTEGRATED
pathophysiology
ProviderStanceScoreEvidence
falcon CONCORDANT 80% skin and end-stage diseased vascular tissue do not indicate increased TGF-β signaling
Falcon describes TGF-beta involvement as uncertain/complex, citing the immunohistochemistry (pSMAD2/CTGF) finding of no increased signaling in end-stage tissue against hypotheses of TGF-beta upregulation.
DOI:10.1038/gim.2017.253
openscientist CONCORDANT 85% The canonical TGF-β/SMAD pathway, while highlighted in the original discovery paper, appears to be a secondary or context-dependent phenomenon rather than the primary driver.
OpenScientist reaches the same conclusion and adds the non-canonical alphavbeta3-integrin/FAK/Src/p38-MAPK pathway as the primary TGF-beta dysregulation route in patient fibroblasts.
PMID:29323665, PMID:29587413

ATS is ultra-rare, with roughly 106 genetically confirmed individuals reported worldwide and an estimated prevalence below 1 per 1,000,000.

UNANIMOUS INTEGRATED
epidemiology
ProviderStanceScoreEvidence
openscientist CONCORDANT 95% As of 2023, approximately 106 genetically confirmed individuals have been reported worldwide, establishing ATS as one of the rarest heritable connective tissue disorders.
OpenScientist gives the ~106 confirmed-individuals figure and an Orphanet prevalence class of <1/1,000,000.
PMID:37619836
falcon CONCORDANT 80% in a recent case series; reliable prevalence estimates are unavailable
Falcon likewise reports incidence <1:1,000,000 live births and 106 genetically confirmed individuals (both stated in the report), while noting that reliable prevalence estimates are unavailable.
DOI:10.1016/j.ejmg.2023.104823

The cardiovascular prognosis is milder than early reports suggested, with the first years of life being the most critical for life-threatening events, and no unequivocal arterial dissections documented.

UNANIMOUS INTEGRATED
prognosis
ProviderStanceScoreEvidence
falcon CONCORDANT 85% but later cohorts report a milder overall course
Falcon contrasts historical mortality up to 40% before age 5 with a milder course in later cohorts, and notes 0 dissections in the tabulated 2018 cohort.
DOI:10.1038/gim.2017.253
openscientist CONCORDANT 90% Our data confirm that the cardiovascular prognosis in ATS is less severe than previously reported and that the first years of life are the most critical for possible life-threatening events
OpenScientist quotes the prognosis-is-less-severe finding and separately states that no unequivocal vascular dissections or ruptures have been documented.
PMID:25373504, PMID:29323665

Beta-adrenergic blockade is used empirically to reduce hemodynamic stress on the arterial wall, with management otherwise largely extrapolated from other aortopathies and unproven by trials.

UNANIMOUS INTEGRATED
treatment
ProviderStanceScoreEvidence
falcon CONCORDANT 90% is used empirically to reduce hemodynamic stress on arterial walls; efficacy is not established and practice is largely extrapolated from other aortopathies
Falcon reports empiric beta-blocker use to reduce hemodynamic stress, with unestablished efficacy and expert-opinion-based practice.
DOI:10.1016/j.ejmg.2023.104823
openscientist CONCORDANT 90% To reduce hemodynamic stress on the arterial wall, beta-adrenergic blocking treatment was prescribed
OpenScientist names beta-blockers as first-line therapy to reduce hemodynamic stress and adds losartan and surgical/catheter interventions.
PMID:37619836

A key species difference amplifies human disease: humans cannot synthesize ascorbate (non-functional GULO), so Slc2a10-deficient mice that retain endogenous ascorbate synthesis are protected and fail to recapitulate the human vascular phenotype, requiring a Gulo;Slc2a10 double knockout to model.

SINGLE LEAD
gene_functionpathophysiology
ProviderStanceScoreEvidence
openscientist CONCORDANT 90% This likely explains why simple Slc2a10 mutant mice fail to recapitulate the human vascular phenotype
OpenScientist details the GULO/ascorbate species difference as a human amplification factor and the need for the Gulo;Slc2a10 double knockout model.
PMID:32307537, PMID:18693279
falcon SILENT —
Falcon only briefly references a zebrafish morpholino model and does not discuss the GULO/ascorbate species difference, mouse protection, or the double-knockout model.

Narrative

Overview

Both providers frame arterial tortuosity syndrome as an ultra-rare autosomal recessive connective tissue disorder caused by biallelic loss-of-function variants in SLC2A10/GLUT10, in which impaired intracellular ascorbate biology produces defective extracellular matrix assembly (fragmented elastic fibers, disorganized collagen) and the hallmark vascular phenotype of arterial tortuosity, elongation, stenosis, and variable aneurysm formation. Falcon is a concise cohort/case-series synthesis; OpenScientist is a comprehensive 15-domain report with deeper molecular mechanism and model-organism coverage.

Agreement

The reports converge on the core genetics (biallelic SLC2A10/GLUT10, autosomal recessive, frequent consanguinity and the Arab p.Ser81Arg founder allele), the ascorbate/dehydroascorbic-acid transporter role of GLUT10, the ECM ultrastructural pathology (fragmented elastin core with peripheral microfibrils of random directionality), the widespread vascular phenotype including pulmonary artery stenosis, the ultra-rarity (~106 confirmed individuals, <1/1,000,000), the milder-than-historically-reported prognosis with infancy as the critical window and no documented dissections, and empiric beta-blockade plus surveillance as the mainstay of management.

Divergence

OpenScientist adds substantial mechanistic depth that Falcon lacks: the explicit "ascorbate compartmentalization disorder" framing, the non-canonical alphavbeta3-integrin/FAK/Src/p38-MAPK TGF-beta route, oxidative-stress and mitochondrial arms, and a detailed model-organism section anchored on the GULO species difference (mice protected by endogenous ascorbate synthesis; Gulo;Slc2a10 double knockout needed). Falcon treats the GLUT10-ascorbate link as a hypothesis and only briefly mentions a zebrafish morpholino model, so it is silent on the GULO amplification factor. The only quantitative divergence is minor and non-contradictory (identifier mapping — OpenScientist lists MONDO:0009005/ORPHA:3342 while the dismech entry uses MONDO:0008818), with no genuine conflicts between the two reports.

Integration

The concordant findings (SLC2A10/GLUT10 biallelic loss of function; ascorbate compartmentalization; ECM fragmentation; generalized arterial tortuosity with stenosis and variable aneurysm; ultra-rare epidemiology; milder prognosis with infancy as the critical window and no dissections; empiric beta-blockade) are suitable for promotion into the disorder YAML with the harmonized statements as anchors.

Not integrated (leads)

The GULO species-difference / human-amplification model insight and the detailed non-canonical TGF-beta and mitochondrial mechanistic arms are retained as research leads pending model-system-versus-human validation, along with speculative therapeutic directions (ascorbate supplementation, gene therapy proof-of-concept).

Cross-provider synthesis comparing falcon (concise cohort/case-series) and openscientist (comprehensive 15-domain) reports. best_matching_text values are verbatim, whitespace-normalized substrings of the cited report files; per-finding citations record what each report leaned on and were not independently fetch-verified here. The header mondo is taken from kb/disorders/Arterial_Tortuosity_Syndrome.yaml (MONDO:0008818); OpenScientist's report instead lists MONDO:0009005 (a coding divergence, not a substantive conflict).